TB Eradication Expenditure
180 likes | 201 Vues
Learn about the costs, funding sources, and main expenditure items of the TB Eradication Programme. Detailed breakdown of expenditures and financial interventions to support eradication efforts.
TB Eradication Expenditure
E N D
Presentation Transcript
TB Eradication Expenditure Angela Robinson Assistant Principal Officer ERAD Division TB Conference Carlton Hotel 9 –10 October 2007
TB Programme – Expenditure Overview • How much does the TB Eradication Programme cost? • How is the TB programme financed? • Main expenditure items, including compensation
TB Programme - Grossexpenditure (not incl. admin costs) €m 1999 49.5 2000 45.5 2001 34.7 2002 40.7 2003 40.1 2004 36.3 2005 39.6 2006 38.3
TB Programme – Gross Expenditure Millions
TB Programme expenditure – sources of funding • National Exchequer • Farmer levies • Estimated €13.9m in 1996 • Estimated €10.4m in 2006 • Further reduction in 2007 • EU contribution
TB Programme – main expenditure items • Vet fees for herd testing • Reactor collection service • Supplies – purchase of tuberculin, kits • Wildlife programme • Research • Compensation • DAFF administrative costs
Main expend items - Vet fees – herd testing • Pre 1996 all testing was paid by DAF • Post 1996 to date farmer pays for one test per year except where reactors are disclosed • Total spend on vet fees in 2006 was €8.59m
Main expend itemsReactor collection service • Reactor collection from farm direct to slaughter plant • Objective: rapid removal minimises risk of spread of disease • Hauliers engaged following tender invitation • Cost of RCS in 2006 was €0.8m
Main expend items -Supplies • Supplies including tuberculin (€4m), supply of kits, lab equipment supplies • Total spend on supplies in 2006 was €5m
Main expend items –Wildlife programme • 2000 Partnership Agreement • Committed to enhancing wildlife strategy • Funding increased from €1m in 2000 to €2.6m in 2006
Main expend items –Research • Funding provided for: • Centre for Veterinary Epidemiology and Risk Analysis (CVERA) • The TB Diagnostics and Immunology Research Centre • The Badger Vaccine project • Various post-graduate studies • Policy advice and epid. and scientific research • Total spend on research 2000 was €1.1m and in 2006 was €2m
Main expend items - Compensation Schemes • On Farm Market Valuation Payment • Income Supplement • Depopulation Grant • Hardship Grant • Penalties up to 100% where there are breaches of terms and conditions, legislation and/or disease control requirements
On Farm Market Valuation - main terms • Replaced reactor grant (flat rate) • Fully rolled out in 2002 • Market value – in line with EU Task Force recommendation - subject to ceilings • €2,800 (inclusive of factory salvage price) per individual animal • €3,500 for one pedigree stock bull per breakdown episode
On-Farm Market Valuation - main terms contd. • Independent valuation • Guideline market prices compiled weekly from selected marts issued to valuers • Salvage value paid by factory to farmer • DAFF pays difference between salvage value and market value • DAFF pays full costs of 1st valuation • Appeal and arbitration mechanisms
Depopulation – main terms • Objective: to compensate farmers for loss of income arising from depopulation • Herdowner must agree to depopulation at the time specified by the Department • Payable for animals removed where full or partial depopulation is considered appropriate
Income Supplement – main terms • Objective: to compensate farmers for loss of income arising from removal of animals • Payable where removal is > than 10% of animals • Depopulation not considered appropriate • Maximum: first 100 animals only
Hardship Grant – main terms • Assists farmers with additional feed costs where animals are retained/fed during periods of restriction • Eligibility period between 1 November and 30 April • Following reactor re-test • No off-farm income • No income from milk sales • Maximum €250.00 per month for a period not exceeding 4 months during eligibility period
Conclusion - Objective of DAFF financial intervention • Compensation • removal of privately owned assets • loss of income arising from restriction of movements • Minimises risk of failure to disclose disease • Payment for herd testing supports regulatory framework of the testing regime to progress eradication • Rapid removal of reactors minimises risk of further spread of disease • Research to underpin eradication/wildlife policy, including in particular, the development of vaccine